Milestone Pharmaceuticals gets NMPA approval for etripamil
Milestone Pharmaceuticals announced NMPA approval of etripamil nasal spray for adult PSVT and a $2.0 million milestone payment.
Milestone Pharmaceuticals announced NMPA approval of etripamil nasal spray for adult PSVT and a $2.0 million milestone payment.Key Highlights:Original SEC Filing: Milestone Pharmaceuticals Inc. [ MIST ] - 8-K - Sep.
03, 2026This is an AI-powered summary.
It may contain inaccuracies.
Consider verify…